Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 2/20 | 0.38 |
| ▸ | CHAT | P28329 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497021 | 0.87 | AURKA (0.43) | AURKAAURKBTTRNR4A1CA12 | |
| SCHEMBL9813360 | 0.84 | AURKA (0.72) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL6051312 | 0.83 | AURKA (0.65) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL11429443 | 0.81 | AURKA (0.73) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL11759180 | 0.81 | AURKA (0.73) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL29532393 | 0.81 | NR4A1 (0.51) | AURKAAURKBTTRNR4A1CHAT | |
| SCHEMBL6615466 | 0.81 | NR4A1 (0.51) | AURKAAURKBTTRNR4A1CHAT | |
| SCHEMBL11431367 | 0.80 | AURKA (0.66) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL159399 | 0.80 | AURKA (0.75) | AURKAAURKBTTRNR4A1SNCA | |
| SCHEMBL30822934 | 0.80 | AURKA (0.75) | AURKAAURKBTTRNR4A1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-0906313-B1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1028962-B1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6399597-B1 | CARBAPENICILLIN ANTIBIOTICS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1032384-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1028962-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1032383-A4 | ANTIBACTERIAL CARBAPENEMS, COMPOSITIONS AND METHODS OF TREATMEMT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6294529-B1 | ANTIBIOTICS BACTERICIDES | MERCK & CO., INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1027352-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6271222-B1 | ANTIBIOTIC | MERCK & CO., INC. | 2001-08-07 | — | — | US | disclosed |
| EP-1027352-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5994343-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5994345-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999020269-A1 | ANTIBACTERIAL CARBAPENEMS, COMPOSITIONS AND METHODS OF TREATMEMT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020270-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020628-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020627-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0906313-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5756725-A | CARBAPENEM NUCLEUS IS SUBSTITUTED AT THE 2-POSITION WITH A NAPHTHOSULTAM LINKED THROUGH A CH2 GROUP | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997040048-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | AURKA 1192/4885AURKB 607/4885TTR 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.